Matrix Metalloproteinases and Colorectal Cancer;Matrix-Metalloproteinasen und Kolorektales Karzinom

Medizinische Klinik

Volumn 98, Issue 12, 2003, Pages 763-770

  Roeb, Elke ^a   Matern, Siegfried ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Colorectal cancer; Invasion; Matrix metalloproteinases; Metastasis

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR; STROMELYSIN; UROKINASE;

BASEMENT MEMBRANE; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; COLORECTAL CANCER; CONNECTIVE TISSUE; GENE IDENTIFICATION; HUMAN; METASTASIS; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; STROMA; TUMOR CELL CULTURE; TUMOR GROWTH;

ANIMALS; COLLAGENASES; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATORS; PROGNOSIS;

EID: 0347419934     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1322-5     Document Type: Review

References (86)

1. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-57.
2. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
3. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
4. Woessner JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix metalloproteinases. San Diego: Academic Press, 1998:1-14.
5. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
6. Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
7. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
8. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113-35.
9. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
10. Roeb E, Matern S. Matrix metalloproteinases: promoters of tumor invasion and metastasis - a review with focus on gastrointestinal tumors. Z Gastroenterol 2001;39:807-13.
11. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
12. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-41.
13. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutical implications. Matrix Biol 1997;15:535-41.
14. Johnsen M, Lund LR, Romer J, et al. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-71.
15. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
16. Collins HM, Morris TM, Watson SA. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001;84:1664-70.
17. Heppner KJ, Matrisian LM, Jensen KA, et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
18. Saito K, Takeha S, Shiba K, et al. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 2000;86:24-9.
19. Nielsen BS, Timshel S, Kjeldsen L, et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996;65:57-62.
20. Johansson N, Vaalamo M, Grénman S, et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999;154:469-80.
21. Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190-6.
22. Parsons SL, Watson SA, Collins HM, et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998;78:1495-502.
23. Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-7.
24. Masson R, Lefebvre O, Noel A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
25. Muller D, Wolf C, Abecassis J, et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993;53:165-9.
26. Porte H, Chastre E, Prevot S, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995;64:70-5.
27. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 2003;39:981-8.
28. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.
29. Murphy G, Kniuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997;15:511-8.
30. Allan JA, Docherty AJ, Barker PJ, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995;309:299-306.
31. Sopara I, Dancewicz A. [A neutral protease from human leucocytes involved in collagen degradation (author's translation).] Przegl Lek 1974;31:435-9.
32. Dubois B, Masure S, Huttenbach U, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999;104:1507-15.
33. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:3279-84.
34. Roeb E, Dietrich CG, Winograd R, et al. Activity and cellular origin of gelatinases in colon and rectal cancer: differential activity of MMP-9. Cancer 2001;92:2680-91.
35. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
36. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998;161:3340-6.
37. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-7.
38. Fridman R, Toth M, Pena D, et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55:2548-55.
39. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
40. Ståhle-Bäckdahl M, Parks WC. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol 1993;142:995-1000.
41. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999;274:13066-76.
42. Pyke C, Ralfkiaer E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993;142:359-65.
43. Emmert-Buck MR, Roth MJ, Zhuang Z, et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994;145:1285-90.
44. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996;74:1161-7.
45. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of amtrix metalloproteinase-9. J Clin Oncol 1996;14:3133-40.
46. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expresssion between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002;80:105-10.
47. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999;20:749-55.
48. Shimizu S, Nishikawa Y, Kuroda K, et al. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996;56:3366-70.
49. Lengyel E, Gum R, Juarez J, et al. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 1995;55:963-7.
50. Moll UM, Youngleib G, Rosinski K, et al. Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 1990;50:6162-70.
51. Unemori F, Hibbs MS, Armento EP. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest 1991;88:1656-62.
52. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70:722-6.
53. Partridge CA, Phillips PG, Niedbala MJ, et al. Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts. Am J Physiol 1997;272:L813-22.
54. Himelstein BP, Conte-Soler R, Bernhard EJ, et al. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994;14:246-58.
55. Tremble PM, Lane TF, Sage EH, et al. SPARC a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular-matrix-dependent pathway. J Cell Biol 1993;121:1433-44.
56. MacDougall JR, Bani MR, Lin Y, et al. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995;55:4174-81.
57. Li J, Brick P, O'Hare MC, et al. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Structure 1995;3:541-9.
58. Roeb E, Behrmann I, Grötzinger J, et al. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J 2000;14:1671-3.
59. Brooks PC, Silletti S, Schalscha TL von, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
60. Roeb E, Schleinkofer K, Kernebeck T, et al. The MMP-9 hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 2002;277:50326-32.
61. Cha H, Kopetzki E, Huber R, et al. Structural basis of the adaptive molecular recognition by MMP-9. Mol Biol 2002;320:1065-79.
62. Harris ED Jr, Krane SM. Collagenases (second of three parts). N Engl J Med 1974;291:605-9.
63. Shiozawa J, Ito M, Nakayama T, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 2000;13:925-9.
64. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
65. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5:108-14.
66. Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-6.
67. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000;87:1215-21.
68. Inuzuka K, Ogata Y, Nagase H, et al. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 2000;93:211-8.
69. Adachi Y, Yamamoto H, Itoh F, et al. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999;45:252-8.
70. Masaki T, Matsuoka H, Sugiyama M, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;84:1317-21.
71. Yamamoto H, Itoh F, Hinoda Y, et al. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin. Biochem Biophys Res Commun 1994;201:657-64.
72. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-36.
73. Crabbe T, Smith B, O'Connell J, et al. Human progelatinase A can be activated by matrilysin. FEBS Lett 1994;345:14-6.
74. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymatic properties. J Biol Chem 1995;270:6691-7.
75. Witty JP, McDonnell S, Newell KJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-12.
76. Malhotra S, Newman E, Eisenberg D, et al. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis Colon Rectum 2002;45:537-43.
77. Takahashi M, Tsunoda T, Seiki M, et al. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002;21:5861-7.
78. Kikuchi R, Noguchi T, Takeno S, et al. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 2000;83:215-8.
79. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002;26:767-71.
80. Gandolfo GM, Conti L, Vercillo M. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Anticancer Res 1996;16:2155-9.
81. Yang JL, Seetoo D, Wang Y, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000;89:431-9.
82. Herszenyi L, Plebani M, Carraro P, et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999;86:1135-42.
83. Skelly MM, Troy A, Duffy MJ, et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997;3:1837-40.
84. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
85. Ganesh S, Sier CF, Heerding MM, et al. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
86. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.